Jan 22, 2019
Lemborexant taken at bedtime had no significant effect on automobile driving performance the next morning in healthy adult ... Read more
Jan 15, 2019
TOKYO and STAMFORD, Conn. – January 15, 2019 – Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Purdue ... Read more
Jan 7, 2019
Partners to research novel targets for reductions in pain STAMFORD, Conn., and BEDFORD, Mass., January 7, 2019 – ... Read more
Nov 6, 2018
STAMFORD, Conn., November 6, 2018 – Purdue Pharma L.P. today announced that the first patient has been enrolled in a ... Read more
Oct 22, 2018
Purdue will support SpineThera’s clinical development program to evaluate sustained-release, injectable treatment options for pain in and near ... Read more
Oct 17, 2018
Long-term efficacy and safety evaluation in patients with insomnia, a sleep-wake disorder, met primary and key secondary efficacy ... Read more
Sep 24, 2018
STAMFORD, Conn. – September 24, 2018 – Marcelo E. Bigal MD, Ph.D. Chief Medical Officer, Purdue Pharma L.P., issued the ... Read more
Sep 6, 2018
Studies Underscore Company’s Ongoing Commitment to Working Collaboratively on Meaningful Solutions to Address the Opioid Crisis STAMFORD, Conn., ... Read more
Sep 6, 2018
Results Show Successful Uptake of Technology and Increased Patient-Provider Communication STAMFORD, Conn., and DANVILLE, Pa. – September 6, ... Read more
Sep 5, 2018
STAMFORD, Conn. and PITTSBURGH, Penn., September 5, 2018 – Purdue Pharma L.P. (Purdue) and Harm Reduction Therapeutics, Inc. today announced ... Read more
for Healthcare Professionals 
for Patients & Caregivers 
Addressing the Crisis 
Partnering 